143468-07-9

Usage

Molecular Structure

1H-Pyrrolo[2,3-b]pyridine-1-carboxylic acid, 6-chloro-, methyl ester is a chemical compound with a unique molecular structure that features a pyrrolopyridine ring system and a carboxyl group.

Functional Groups

The carboxyl group and the methyl ester group are the two main functional groups present in 1H-Pyrrolo[2,3-b]pyridine-1-carboxylic acid, 6-chloro-, methyl ester, which contribute to its reactivity and properties.

Molecular Weight

The molecular weight of 1H-Pyrrolo[2,3-b]pyridine-1-carboxylic acid, 6-chloro-, methyl ester is [Molecular Weight].

Physical State

1H-Pyrrolo[2,3-b]pyridine-1-carboxylic acid, 6-chloro-, methyl ester is a solid at room temperature.

Solubility

1H-Pyrrolo[2,3-b]pyridine-1-carboxylic acid, 6-chloro-, methyl ester is soluble in [Solvent 1], [Solvent 2], and [Solvent 3], but insoluble in [Solvent 4].

Chemical Reactivity

1H-Pyrrolo[2,3-b]pyridine-1-carboxylic acid, 6-chloro-, methyl ester is reactive towards [Reagent 1], [Reagent 2], and [Reagent 3]. It can undergo [Reaction 1], [Reaction 2], and [Reaction 3] to form various derivatives.

Pharmaceutical Applications

1H-Pyrrolo[2,3-b]pyridine-1-carboxylic acid, 6-chloro-, methyl ester is commonly used as an intermediate in the synthesis of various pharmaceutical drugs and as a building block in the development of new drug candidates for the treatment of various medical conditions.

Safety and Handling

1H-Pyrrolo[2,3-b]pyridine-1-carboxylic acid, 6-chloro-, methyl ester should be handled with care and proper safety measures, as it may be toxic or hazardous under certain conditions. It should be stored in a [Storage Condition].

Upstream product

• 96-34-4 methyl chloroacetate 
• 55052-24-9 1H-Pyrrolo[2,3-b]pyridine-7-oxide 
• 271-63-6 7-Azaindole 
• 79-22-1 methyl chloroformate 
• 2290-65-5 trimethylsilyl isothiocyanate 

Downstream Products

• 189882-33-5 1H-pyrrolo[2,3-b]pyridine-6-carbonitrile 
• 383875-59-0 6-chloro-1H-pyrrolo[2,3-b]pyridine-3-carboxaldehyde 
• 1332605-39-6 6-chloro-1-(p-tolylsulfonyl)pyrrolo[2,3-b]pyridine 
• 1346151-47-0 6-methyl-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridine 
• 533939-04-7 6-ethyl-1H-pyrrolo[2,3-b]pyridine 
• 1420532-25-7 N-ethyl-N-(2-(6-ethyl-1H-pyrrolo[2,3-b]pyridin-1-yl)-5-(trifluoromethyl)benzyl)cyclopropanecarboxamide 
• 824-51-1 6-methyl-1H-pyrrolo<2,3-b>pyridine 
• 896722-51-3 1-benzenesulfonyl-6-methyl-1H-pyrrolo[2,3-b]pyridine 
• 896722-50-2 1-benzenesulfonyl-6-chloro-1H-pyrrolo[2,3-b]pyridine 
• 1303587-30-5 N-(pyridin-2-yl)-6-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-1-carboxamide 
• 1303588-56-8 6-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine 
• 1303588-55-7 6-(3-(trifluoromethyl)phenyl)-1H-pyrrolo[2,3-b]pyridine 
• 845993-56-8 methyl 6-[4-(methylsulfonyl)phenyl]-7-azaindole-1-carboxylate 
• 55052-27-2 6-chloro-7-azaindole 

Relevant academic research and scientific papers

Synthesis of new substituted 2-(trimethylstannyl)indoles

Synthesis of the previously unreported 2-(trimethylstannyl)indole derivatives, 5-bromo-1-(tert-butoxycarbonyl)-2-(trimethylstannyl)-1H-indole, 6-bromo-1-(tert-butoxycarbonyl)-2-(trimethylstannyl)-1H-indole, 1-(tert-butoxycarbonyl)-2-(trimethylstannyl)-1H-indole-5-carbonitrile, 1-(tert-butoxycarbonyl)-2-(trimethylstannyl)-1H-indole-6-carbonitrile and 1-(tert-butoxycarbonyl)-2-(trimethylstannyl)-1H-pyrrolo[2,3-b] pyridine-6-carbonitrile, is described. Georg Thieme Verlag Stuttgart.

Synthetic method of 6-chloro-7-azaindole

The invention discloses a synthetic method of 6-chloro-7-azaindole, belonging to the field of chemical synthesis. 7-azaindole is taken as a raw material, and the 6-chloro-7-azaindole is synthesized by three actions of N-oxidation, chlorination and hydrolysis. The process route is optimized, and the yield is improved by 70% or more, and is improved by 7% compared with the prior art. The improved synthetic route is simple to operate and feasible, the economic benefits are effectively improved, and large-scale industrial promotion is facilitated.

NEW CRTH2 ANTAGONISTS

The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

ANTICANCER AGENT

An anticancer agent comprising a compound represented by the formula (I) [R1 represents hydrogen atom, hydroxyl group, a C1-6alkoxy group and the like; R2 and R3 represents hydrogen atom, a halogen atom, a C1-6alkyl group and the like; R4 represents hydrogen atom, a C1-6alkyl group, a C1-6alkylsulfonyl group and the like; R5 represents hydrogen atom or a substituent; .... represents a single bond or a double bond; R6 and R7 represents hydrogen atom, a C1-6alkyl group and the like; R8 represents hydrogen atom, a C1-6alkyl group and the like; A represents -O-, -S-, or - CH2-; D represents -C= or -N=; X represents methylene group, -O-, or -CO-; Q represents -N= or -C(R8)=; and Y represents a heterocyclic group or amino group], which shows a superior inhibitory activity against pim-1 kinase.

Scaffold-hopping strategy: Synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents

Utilizing scaffold-hopping drug-design strategy, we sought to identify a backup drug candidate for BPR0L075 (1), an indole-based anticancer agent. For this purpose, 5,6-fused bicyclic heteroaromatic scaffolds were designed and synthesized through shufflin

BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS

Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

7-AZAINDOLE DERIVATIVES AS COX2 INHIBITORS

Compounds of formula (I) or pharmaceutically acceptable salts thereof are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever and inflammation of a variety of conditions and diseases.

Regioselective functionalization of 1H-pyrrolo[2,3-b]pyridine via its N-oxide

Selective functionalization of 1H-pyrrolo[2,3-b]pyridine (7-azaindole) at the 6-position was achieved by Reissert-Henze type reaction. Thus, halogeno (Cl, Br, I), cyano and thiocyanato groups were directly introduced to the pyridine ring of 7-azaindole.